Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple Combination Therapy (Semaglutide, Empagliflozin, Pioglitazone) vs Standard Therapy in Newly Diagnosed T2DM
NCT06946628Phase 3Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2025
- Primary completion
- Dec 2028
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of semaglutide, empagliflozin and pioglitazone in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Diabetic remission rate. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06946628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06946628.